Granules India began as a single-minded bet on making paracetamol cheaper than anyone else, and that instinct - own the molecule from raw material to finished pill - now powers a pharmaceutical company that has climbed from bulk chemicals to complex generics and peptide science. Founded in 1984 by Dr. Krishna Prasad Chigurupati as Triton Laboratories, it listed in 1995 and has since moved through four deliberate phases: foundation, forward integration into finished dosages, scale, and now a transformation into high-barrier segments like controlled substances and peptide CDMO (contract development and manufacturing). The recurring approach is vertical integration - making the active ingredient, the intermediate, and the final tablet under one roof - so that cost advantage and supply-chain control compound at every step. # Business segments Four engines at different stages - a finished-dosage powerhouse that is the main growth driver, two foundational manufacturing engines that supply it and external customers, and a newly acquired peptide CDMO platform - all built on the same vertical-integration logic. ## 1. Finished Dosages: the strategic growth engine **The company makes the final tablets, capsules and oral solutions that patients take, selling them directly in regulated markets, with a deliberate shift from high-volume generics toward complex, hard-to-copy products where the real pricing power sits.** - **Complex generics are taking over the mix** - products with high entry barriers from formulation difficulty, IP strategy or compliance now make up 43% of the portfolio, up from 31% a year earlier, while integrated generics fell from 63% to 52%. Complex generics contributed 49% of total revenue in the third quarter of FY26, nearly double the 27% share a year before. - **First-to-file bets create exclusivity windows** - the company has secured Sole First-to-File status for two complex generics: an amphetamine extended-release tablet and a sodium oxybate oral suspension for narcolepsy, giving it 180-day exclusivity opportunities that let it launch without a crowd of competitors. - **The US is the anchor, but Europe is the accelerator** - North America still provides 74% of finished-dosage revenue, yet Europe grew 81% year-on-year in FY26 and 151% in the final quarter, driven by a partnership model where Granules supplies dossier-ready products to strong local generic players. - **ADHD is a franchise, not just a product line** - the company controls the full chain for ADHD medicines from API manufacturing to final packaging in the US, ranks fourth among US generic companies in controlled substances, and runs a dedicated R&D centre in Chantilly, Virginia, close to the FDA for faster regulatory dialogue. - **Manufacturing scale that doubles as a moat** - the Gagillapur site is the world’s largest single-location multi-unit pellet system facility with 26.8 billion dosages of capacity, and the newer Genome Valley site adds another 10 billion, giving the company the kind of volume that large US buyers look for when building a supplier panel. ## 2. Active Pharmaceutical Ingredients: the cost-leadership backbone **Granules makes the core chemical substances that give drugs their therapeutic effect, operating the world’s largest paracetamol API plant and supplying both its own finished-dosage business and marquee external customers.** - **Paracetamol at global scale** - the company holds roughly 30% of the world market for paracetamol API and aims to reach about 50%, using the cash generated by this and metformin to fund growth in more complex products. The Bonthapally facility alone has API capacity of 34,560 tonnes per year. - **The API plant feeds the formulations engine** - many US customers who originally bought paracetamol API are being converted to finished-dosage buyers, so the API business acts as both a standalone supplier and a customer-acquisition funnel for the higher-value formulations segment. - **Backward integration is the defence against supply shocks** - key raw materials like Para Amino Phenol (PAP) for paracetamol have historically been in short supply, and India imports nearly 68% of its APIs by value from China, so the company is developing indigenous vendors and alternative supply routes to de-risk the chain. - **Regulatory reach through 109 global filings** - the company holds 47 US Drug Master Files, 21 European Certificates of Suitability, and filings across Korea, China, Canada, Brazil and Japan, which means its APIs are pre-qualified for use by formulators in most major regulated markets. ## 3. Pharmaceutical Formulation Intermediates: the bridge nobody else built **Granules invented the commercial category of pre-formulation intermediates - a ready-to-compress granule mix that lets finished-dosage manufacturers skip several processing steps - and it remains one of the world’s largest producers of these intermediates.** - **Drum-to-hopper economics** - PFIs eliminate the customer’s need for pre-formulation studies, reduce testing and capital expenditure, and arrive with release properties already matched to brand leaders, so a tablet maker can go straight from the drum to the compression machine. - **Six-tonne batch power** - the company runs one of the largest PFI facilities in the world with six tonnes of batch processing capacity, giving it economies of scale that smaller competitors cannot match. - **A dual-purpose engine** - PFI production at Gagillapur and Jeedimetla serves external customers but is increasingly consumed internally by Granules’ own finished-dosage lines, which is why the segment’s revenue share has fallen from 20% to 10% even as its strategic importance has grown. ## 4. Peptide CDMO: the new science platform **Through the acquisition of Swiss-based Senn Chemicals in April 2025, Granules entered the contract development and manufacturing of peptide therapeutics - the fast-growing class of drugs that includes GLP-1 anti-obesity treatments - operating a two-continent model that pairs Swiss R&D with Indian scale.** - **Bought, not built from scratch** - Senn Chemicals, founded in 1963 and Swissmedic-approved, brought a live customer book spanning big pharma, biotech start-ups and cosmetic companies, plus both liquid-phase and solid-phase peptide synthesis capabilities. - **Swiss precision, Indian capacity** - the Zurich site handles peptide API and is being upgraded for more capacity, while a brownfield intermediates facility is under construction in India and an Indian peptide API plant is in planning, so the cost structure improves as volumes move east. - **The market tailwind is structural** - global sales of peptide-based anti-obesity and anti-diabetic therapies have already crossed $50 billion annually and are projected to reach $100-150 billion by 2030, which means even a small share of the CDMO pool is a material opportunity. - **Positive at the operating line within three quarters** - the peptide business contributed ₹1,593 million in FY26 revenue and turned EBITDA-positive in the fourth quarter, the third quarter after the acquisition closed. # Group structure and partners **A parent company in Hyderabad with US manufacturing and distribution subsidiaries that provide direct regulated-market access, a Swiss peptide CDMO held through an Indian subsidiary, and a partnership model in Europe that turns local generic players into distribution channels.** - **Granules Pharmaceuticals, Inc. (GPI)** - the 100% US subsidiary in Chantilly, Virginia, manufactures finished dosages (1.5 billion capacity), markets products under its own label, and has climbed from 74th to 27th among US generic companies by sales value in five years. It absorbed the former US sales arm (GUSA) in April 2025 and now also houses the consumer health packaging business. - **Granules Consumer Health (GCH)** - a step-down subsidiary operating an 80,000-square-foot packaging facility in Virginia with two OTC and one prescription packaging line, supplying private-label store-brand partners in the US. - **Ascelis Peptides (formerly Granules Peptides)** - the wholly owned Indian subsidiary that holds Senn Chemicals AG and runs the peptide R&D pipeline, including a lab at IIT Hyderabad collaborating with the Zurich team on live customer projects. - **Granules Life Sciences (GLS)** - the 100% subsidiary that owns the Genome Valley finished-dosage facility with 10 billion dosages of USFDA-approved capacity, now shipping prescription products. - **European partnership model** - rather than building its own sales force, the company partners with strong European generic players and country-level distributors, a model it plans to extend to Latin America. The legacy UK marketing subsidiary was voluntarily dissolved in March 2025 as the model shifted.